Financial PerformanceThe company's third-quarter sales growth is strong, with an increase of 7.6%, and there are no negative impacts from trading days, indicating a positive outlook.
Product InnovationUS Hips has recently outperformed the market, following the same trend as US Trauma last year, after the introduction of the short-stem CATALYSTEM hip platform.
Shareholder ValueA $500 million share buyback is planned for the second half of the year, which could increase shareholder value.